Corcept tries to repeat the glucocorticoid trick
Nenocorilant features among the latest industry projects newly into phase 1.
The conjugate enthusiasm bypasses Mythic
The private ADC company is being wound down.
Henlius and Ottimo join the bispecific bundle
Two new PD-(L)1 x VEGF projects have entered the clinic.
Syndax switches first-line plans
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
BeOne starts another front-line sonrotoclax fight
The new phase 3 trial, in first-line CLL, is expected to begin in January 2026.
Lung toxicity deaths halt ifinatamab
Ideate-Lung02 goes on global clinical hold.
J-Pharma chases Telix in LAT1
But the Japanese group is focused on biliary tract cancer rather than glioblastoma.
Enhertu completes its front-line march
Astra and Daiichi bag FDA approval based on Destiny-Breast09.
Ringside sends Immunome towards filing
On a cross-trial basis varegacestat beats Ogsiveo.
There’s no stopping CDH17
No fewer than four ADCs with this target start human testing.
